Kelun Group Sustainability Profile
Kelun Group, officially known as Kelun Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in China (CN). Founded in 2004, the company has rapidly expanded its operations across major regions, including Asia, Europe, and North America, establishing a strong global presence. Specialising in the research, development, and manufacturing of high-quality generic and innovative drugs, Kelun Group is recognised for its commitment to advanced biopharmaceuticals and injectable products. The company’s unique approach to drug formulation and production has positioned it as a leader in the market, with notable achievements in regulatory compliance and product quality. With a focus on enhancing healthcare solutions, Kelun Group continues to make significant strides in the pharmaceutical sector, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Kelun Group's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kelun Group's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kelun Group's reported carbon emissions
In 2024, Kelun Group reported total carbon emissions of approximately 2,845,549,250 kg CO2e, with Scope 1 emissions accounting for about 2,361,763,170 kg CO2e and Scope 2 emissions at approximately 483,786,080 kg CO2e. This represents an increase from 2023, when total emissions were about 2,659,459,920 kg CO2e, with Scope 1 emissions of approximately 2,190,590,170 kg CO2e and Scope 2 emissions of about 468,869,750 kg CO2e. Kelun Group's emissions data is cascaded from its parent company, Sichuan Kelun Pharmaceutical Co., Ltd., which is the source of the reported figures. The company has not disclosed any Scope 3 emissions data, nor has it set specific reduction targets or climate pledges as part of its sustainability initiatives. Despite the lack of formal reduction commitments, the company is part of a broader industry context that increasingly prioritises carbon reduction and sustainability. As a current subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., Kelun Group's emissions performance is aligned with the parent company's environmental strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 2,190,590,170 | 0,000,000,000 |
| Scope 2 | 468,869,750 | 000,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Kelun Group's Industry?
How Carbon Intensive is Kelun Group's Location?
Kelun Group's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kelun Group has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
